Work

Granuloma annulare treated with certolizumab following the development of antidrug antibodies to adalimumab

Year: 2025

Type: article

Abstract: Granuloma annulare (GA) is a chronic granulomatous skin disorder of unclear etiology characterized by annular plaques and erythematous papules.1 Although localized forms of GA may resolve spontaneously, the generalized variant is often chronic and resistant to therapy.2 First-line therapies often include antimalarials (eg, hydroxychloroquine), narrowband ultraviolet B, and intralesional triamcinolone, with adjuncts such as doxycycline or pentoxifylline for partial responders.3 Second-line treatments include tumor necrosis factor-alpha (TNF-α) inhibitors, which have been used off-label for recalcitrant GA and have shown efficacy in some cases.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2025.03.028

Authors: Ayelet I. Rubenstein, Jina Chung, Misha Rosenbach

Institutions: University of Pennsylvania, Hospital of the University of Pennsylvania

Language: English

Topic: Skin Diseases and Diabetes

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $750